News & Events

Rather than failing, harm reduction strategies, as articulated by Fiellin and colleagues in the New England Journal of Medicine is generating real benefits to patients and society.

The Pain Management Collaboratory Coordinating Center, a Yale-based research center that supports 16 large-scale pragmatic clinical trials of non-drug approaches to managing pain, has been awarded a funding extension to continue its work for six years.

A nationwide survey of U.S. psychiatric hospitals shows that fewer than 50% offer buprenorphine, methadone, and/or naltrexone, lifesaving medications that can treat opioid use disorder.

Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. Screening efforts for this cancer focus on individuals diagnosed with viral hepatitis or those known to have irreversible liver scarring, or cirrhosis. Due in part to increasing rates of obesity, another major risk factor is emerging, metabolic dysfunction-associated steatotic liver disease (MASLD), but factors associated with MASLD are not included in current screening practices. In response, researchers at Yale have developed and validated a new risk score for hepatocellular carcinoma that considers these factors. Their work, “Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis” was published on November 6, 2024, in JAMA Network Open.

Yale BIDS faculty, staff, and students will have a strong presence at the AMIA 2024 Annual Symposium this November in San Francisco, CA.

A research team led by lead author Galina A. Portnoy, PhD, assistant professor of psychiatry, found that bidirectional intimate partner violence was the most common relationship violence pattern, with no differences in gender between who experienced and used violence in the relationship.

A new multi-institutional study has found there was a dramatic decline in thyroid cancer diagnoses during the COVID-19 pandemic, raising concerns about a potential wave of more advanced cancer cases in the future.

Funded by the National Library of Medicine, the project aims to improve the reliability of AI-generated responses in medical applications, ensuring more accurate and trustworthy information to support better health care decisions.

The Yale Conference for Alcohol Research and Education (YCARE) 2024 will take place on Saturday, October 19, 2024. The event is a dynamic day of learning, interaction, and collaboration focused on the theme of alcohol research. This year’s in-person event will feature podium talks, breakout sessions, a panel discussion, poster presentations, and more avenues to learn from and network with colleagues.